Recently, another monoclonal antibody caplacizumab that targets the A1 domain of the ADAMTS13 inhibiting interaction between platelets and VWF multimers and a recombinant ADAMTS13 are being investigated in clinical trials as a potential therapy for TTP [8]. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.